Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -4.60% is 350% below its 5-year average of -1.02%, around the middle of its 5-year range (-15.18%–10.52%).
As of the fiscal period ended Tuesday, September 30, 2025. 25.68% below its 12-month average of -3.66%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-03-31): -0.48%.
RETURN ON ASSETS (ROA)
-4.60%
RETURN ON ASSETS (ROA) AVG TTM
-3.66%
RETURN ON ASSETS (ROA) AVG 3Y
-5.21%
RETURN ON ASSETS (ROA) AVG 5Y
-1.02%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-25.68%
CURRENT VS 3Y AVG
+11.67%
CURRENT VS 5Y AVG
-350.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+85.73%
vs the sector median at left
BGM Group Ltd.
Market Cap
$118.12M
Return on Assets (ROA)
-4.60%
TTM Avg
-3.66%
3Y Avg
-5.21%
5Y Avg
-1.02%
Market Cap
$119.15M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$119.17M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$119.78M
Return on Assets (ROA)
-110.24%
TTM Avg
-77.16%
3Y Avg
-67.85%
5Y Avg
-53.38%
Market Cap
$121.37M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$121.23M
Return on Assets (ROA)
-26.48%
TTM Avg
-24.24%
3Y Avg
-21.83%
5Y Avg
-17.99%
Market Cap
$121.25M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$114.84M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
Market Cap
$114.47M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $118.12M | -4.60% | -3.66% | -5.21% | -1.02% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.15M | -53.26% | -24.98% | -43.10% | -143.56% |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.17M | -49.93% | -95.40% | -72.70% | -57.07% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.78M | -110.24% | -77.16% | -67.85% | -53.38% |
| Cibus, Inc. (CBUS)vs › | $121.37M | -31.33% | -56.73% | -59.49% | -64.55% |
| Seer, Inc. (SEER)vs › | $121.23M | -26.48% | -24.24% | -21.83% | -17.99% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | -1.70% | -35.34% | -51.03% | -36.99% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.84M | -134.18% | -145.83% | -164.39% | -180.40% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | -0.05% | -38.03% | -60.31% | -59.32% |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | -19.30% | -19.59% | -15.38% | -15.18% |
ROA
-4.6%
ROE
-5.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -4.60% |
| 2024-09-30 | -2.72% |
| 2023-09-30 | -15.18% |
| 2022-09-30 | 1.67% |
| 2021-09-30 | 4.18% |
| 2020-09-30 | 10.52% |
| 2019-09-30 | 15.12% |
| 2018-09-30 | 15.51% |
| 2017-09-30 | 4.24% |
